Home » Stocks » ENTX

Entera Bio Ltd. (ENTX)

Stock Price: $5.19 USD -0.12 (-2.26%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $5.20 +0.01 (0.19%) Jul 26, 7:23 PM
Market Cap 126.25M
Revenue (ttm) 480,000
Net Income (ttm) -16.55M
Shares Out 23.78M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $5.19
Previous Close $5.31
Change ($) -0.12
Change (%) -2.26%
Day's Open 5.29
Day's Range 5.11 - 5.40
Day's Volume 85,639
52-Week Range 1.00 - 10.16

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON and JERUSALEM, June 28, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will conduct a con...

4 weeks ago - GlobeNewsWire

Entera (ENTX) gains on positive results from a mid-stage study on its osteoporosis candidate at six months.

1 month ago - Zacks Investment Research

Entera Bio Ltd (NASDAQ: ENTX) shares rallied higher Wednesday after the company announced it saw positive results from its final six-month bone mineral density results from the completed Phase 2 clinica...

1 month ago - Benzinga

Today, investors in ENTX stock are seeing gains of approximately 40% as the company announced results from one of its clinical trials. The post ENTX Stock: The Huge FDA News Sending Entera Bio Soaring a...

1 month ago - InvestorPlace

The shares of Entera Bio Ltd.

1 month ago - Schaeffers Research

Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) are among the biggest biopharma movers Wednesday.

Other stocks mentioned: BLPH, ORPH
1 month ago - Benzinga

Entera Bio Ltd (NASDAQ: ENTX) shares are trading higher by 47.66% at $6.63 Wednesday after the company announced the topline Phase 2 clinical trial of EB613 met its primary and key secondary endpoints. ...

1 month ago - Benzinga

Current & Former Penny Stocks To Watch Before July The post 8 Hot Biotech Penny Stocks For Your July 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other stocks mentioned: BLPH, GTBP, OCGN, ORPH
1 month ago - PennyStocks

BOSTON and JERUSALEM, June 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule and biologic therapeutics, announced the final 6-mo...

1 month ago - GlobeNewsWire

Entera Bio (ENTX) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

1 month ago - Zacks Investment Research

‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 3-Month Primary Endpoint; Final Data Including BMD Expected Q2:21 ‒

2 months ago - GlobeNewsWire

Entera Bio's (ENTX) stock price is being driven by encouraging data from phase II study on EB613, its investigational orally delivered treatment for osteoporosis

2 months ago - Zacks Investment Research

Stocks of BioNTech (BNTX), Ocugen (OCGN), Rubius Therapeutics (RUBY) and Entera Bio (ENTX) are up more than 100% this year so far.

Other stocks mentioned: BNTX, OCGN, RUBY
2 months ago - Zacks Investment Research

BOSTON and JERUSALEM, April 20, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that Ron Mayron has ...

3 months ago - GlobeNewsWire

BOSTON and JERUSALEM, Israel, April 15, 2021 (GLOBE NEWSWIRE) --  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appoint...

3 months ago - GlobeNewsWire

BOSTON and JERUSALEM, April 06, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company will del...

3 months ago - GlobeNewsWire

‒ Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial ‒ ‒ Final Data , Including Bone Mineral Density, Expected in Q2:21 ‒ ‒ FDA Approv al of EB613 IND for the Treatment of O steoporosis Enables I...

4 months ago - GlobeNewsWire

ENTX stock continues to sky rocket, leading investors to question halted stocks. Here's what you should know now.

4 months ago - InvestorPlace

Entera Bio Ltd (NASDAQ: ENTX) shares are trading higher on heavy volume Friday after the company announced the Phase 2 clinical trial of EB613 met its primary endpoint. According to Entera, EB613 is an ...

4 months ago - Benzinga

BOSTON and JERUSALEM, March 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business an...

4 months ago - GlobeNewsWire

Entera Bio (ENTX) stock is soaring higher on Thursday following an update from the biotech company about its osteoporosis treatment. The post ENTX Stock: 11 Things for Entera Bio Investors to Know as Sh...

4 months ago - InvestorPlace

Entera Bio Ltd (NASDAQ: ENTX) is soaring in the premarket in reaction to positive topline data from the Phase 2 trial of EB613 in postmenopausal female subjects with osteoporosis (low bone mineral densi...

4 months ago - Benzinga

‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data ‒ ‒ Final Analysis of 6-Month Data , Including Change in Bone Mineral Density, Expected in Q2:21 ‒

4 months ago - GlobeNewsWire

BOSTON and JERUSALEM, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to Shareholders...

6 months ago - GlobeNewsWire

EB613 Phase 2 Placebo-Controlled, Dose-Ranging Study Ongoing in Israel with Complete 3 Month Biomarker Data expected in Q1:21 and Final Bone Mineral Density, or BMD, Data Expected in Q2:21 EB613 Phase 2...

7 months ago - GlobeNewsWire

Entera Bio Ltd. (ENTX) CEO Roger Garceau on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

‒ Completed E nrollment in Phase 2 Clinical Trial of EB613, P ositioned as the F irst P otential O ral B one B uilding P roduct to T reat O steoporosis ‒ ‒ Positive Interim 6-Month Bone Mineral Density ...

8 months ago - GlobeNewsWire

BOSTON JERUSALEM, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and fin...

8 months ago - GlobeNewsWire

‒ Company Expect s to Report Interim 3 Month Bio m arker Data for All Enrolled Patients in Q1:21 with Final Bone Mineral Density, or BMD, Data Expected in Q2:21 ‒

8 months ago - GlobeNewsWire

BOSTON and JERUSALEM, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its mana...

10 months ago - GlobeNewsWire

Entera Bio Ltd. (ENTX) Interim CEO Roger Garceau on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

‒ 6-Month Interim Data Indicate EB 613 Has Meaningful and Positive Impact on  Lumbar Spine Bone Mineral Density (BMD) in a Dose Dependent Manner – ‒ Company Expects to Complete Patient Enrollment in...

11 months ago - GlobeNewsWire

BOSTON and JERUSALEM, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business a...

11 months ago - GlobeNewsWire

BOSTON and JERUSALEM, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its Board of D...

11 months ago - GlobeNewsWire

BOSTON and JERUSALEM, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its manag...

11 months ago - GlobeNewsWire

‒ Approximately 85% of Clinicians Surveyed Likely to Prescribe Oral Parathyroid Hormone (PTH) to Treat Moderate to Severe Osteoporosis ‒

1 year ago - GlobeNewsWire

‒ Institutional Review Boards (IRBs) Approve Amended Phase 2 Protocol with Newly Enrolled Patients Receiving a 2.5 mg Dose, 1.5 mg Dose, or Placebo ‒

1 year ago - GlobeNewsWire

Entera Bio Ltd.'s (ENTX) CEO Adam Gridley on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

‒ Statistically Significant One Month Increases in P1NP Biomarker  from First 50% of Patients with Highest Dose of EB613 ‒ ‒ Company to Follow Patients in the Phase 2 Clinical Trial of EB613 through S...

1 year ago - GlobeNewsWire

Entera Bio Ltd. (ENTX) CEO Adam Gridley on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

BOSTON and JERUSALEM, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today that it increased the...

1 year ago - GlobeNewsWire

BOSTON and JERUSALEM, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today it has closed a priva...

1 year ago - GlobeNewsWire

Entera Bio Ltd. (ENTX) CEO Adam Gridley on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today provided a corporate update and reported financial results for the third quarter ended September 30, 2019.

1 year ago - GlobeNewsWire

BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as i...

1 year ago - GlobeNewsWire

JERUSALEM and BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced the presentation of positive results from its pharmacokinetic (PK) and pharmacodynamic (PD) stud...

1 year ago - GlobeNewsWire

Entera Bio Ltd. (ENTX) CEO Adam Gridley on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

JERUSALEM and BOSTON, Aug. 20, 2019 (GLOBE NEWSWIRE) --  Entera Bio Ltd. (NASDAQ: ENTX) today provided a corporate update and reported financial results for second quarter ended June 30, 2019.

1 year ago - GlobeNewsWire

Entera Bio Ltd. (ENTX) CEO Phillip Schwartz on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About ENTX

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collabora... [Read more...]

Industry
Biotechnology
IPO Date
Jun 28, 2018
CEO
Adam Gridley
Employees
19
Stock Exchange
NASDAQ
Ticker Symbol
ENTX
Full Company Profile

Financial Performance

In 2020, Entera Bio's revenue was $365,000, an increase of 54.66% compared to the previous year's $236,000. Losses were -$9.98 million, -7.52% less than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Entera Bio stock is "Buy" and the 12-month stock price forecast is 12.00.

Price Target
$12.00
Analyst Consensus: Buy